Year None2024202320222021202020192018201720162015 Dec 19 Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results Dec 17 Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference Dec 17 EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion Dec 16 Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year Dec 9 Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma Dec 7 Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab Nov 15 Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU) Nov 13 Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH Nov 11 Regeneron Announces Investor Conference Presentations Nov 6 Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Next page › Last page »